Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.
The likelihood of finding an underlying genetic cause of short stature in children is markedly increased if they have additional factors such as dysmorphic facial features or skeletal dysplasia, say researchers.
Recombinant human growth hormone appears to have a positive effect on growth in children with Kabuki Syndrome, shows an open-label study.
A cohort study of healthy infants has characterised the relationships between circulating levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 and changes in body length and weight in the first year of life.
A phase 2 study of macimorelin in children with suspected growth hormone deficiency shows similar results to those established in adults.
The human leukocyte antigen polymorphisms that increase the risk of type 1 diabetes are linked to growth and insulin-like growth factor-I levels during infancy, say researchers.
The heiGHt Trial investigators report that once-weekly treatment with lonapegsomatropin offers noninferior and indeed superior annualised height velocity to that achieved with daily somatropin for children with growth hormone deficiency.